Dupilumab Treatment Reduces Hospitalizations in Adults With Moderate-to-Severe Atopic Dermatitis

• Published in: The journal of allergy and clinical immunology in practice (Cambridge, MA) Vol. 10; no. 5; pp. 1279 - 1285.e1
• Main Authors: Silverberg, Jonathan I., Rubini, Norma P.M., Pires, Mario C., Rossi, Ana B., Zhang, Annie, Chen, Zhen, Levit, Noah A., Chao, Jingdong, Shumel, Brad, Bégo-Le Bagousse, Gaëlle
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-05-2022; Elsevier Limited
• Subjects: Adult; Adults; Antibodies, Monoclonal, Humanized; Atopic dermatitis; Clinical trials; Corticosteroids; Cytokines; Dermatitis; Dermatitis, Atopic - complications; Dermatitis, Atopic - drug therapy; Double-Blind Method; Dupilumab; Eczema; Flares; Hospitalization; Humans; Infections; Monoclonal antibodies; Patients; Resource utilization; Severity of Illness Index; Treatment Outcome; United States > US; RR; Resource utilization; RCT; TCS; qw; PY; Hospitalization; Atopic dermatitis; q4w; SAE; Flares; q2w; Dupilumab
• ISSN: 2213-2198; 2213-2201
• DOI: 10.1016/j.jaip.2021.11.034

Refractory disease, flares, or infections in atopic dermatitis (AD) can lead to hospitalizations.
To compare hospitalization rates among adults with moderate-to-severe AD treated with dupilumab versus control.
Data from 7 randomized, placebo-controlled trials of dupilumab (300 mg every 2 weeks [q2w] and/or weekly [qw]; with or without topical corticosteroids) were analyzed.
Patients in the dupilumab 300 mg q2w, qw, and combined dupilumab (q2w and qw; n = 1,841) groups compared with patients in the control group (n = 1,091) had lower rates of all-cause hospitalizations (5.8, 2.7, and 3.8 events, respectively, vs 9.0 events per 100 patient-years [PY]; all P < .05 [49%, 71%, and 62% risk reduction, respectively]); AD-related hospitalizations (2.0, 0.4, 1.0 events vs 4.1 events per 100 PY; P < .05 for qw and dupilumab combined [91% and 79% risk reduction, respectively]); as well as reduced overall duration of AD-related hospitalization (10.9, 7.3, and 8.6 d vs 38.9 d per 100 PY).
Among adults with moderate-to-severe AD, treatment with dupilumab versus control was associated with significant reductions in all-cause and AD-related hospitalization rates, and shorter duration of AD-related hospitalization.